home / stock / rfl / rfl news

RFL News and Press, Rafael Holdings Inc. Class B From 12/01/20

Stock Information
Company Name: Rafael Holdings Inc. Class B
Stock Symbol: RFL
Market: NYSE
Website: rafaelholdings.com
Menu
RFL RFL Quote RFL Short RFL News RFL Articles RFL Message Board
Get RFL Alerts

News, Short Squeeze, Breakout and More Instantly...
RFL - Rafael Pharmaceuticals Partners with Sara's Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue

CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it will initiate a Phase 2 clinical trial of CPI-613 ®...
RFL - Rafael Pharmaceuticals Partners with Sara's Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft

CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it will initiate a Phase 2 clinical trial of CPI-613® (devi...

RFL - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer

CRANBURY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted Fas...

RFL - Tracking Kahn Brothers Portfolio - Q3 2020 Update

Kahn Brothers’ 13F portfolio value decreased from $592M to $528M this quarter. Patterson-UTI was increased while reducing Merck, Seaboard, Sterling Bancorp, and Hologic. The portfolio continues to be very concentrated with the top five positions accounting for ~48% of the 1...
RFL - Rafael Holdings Reports Fourth Quarter and Full Fiscal Year 2020 Results

Rafael Holdings Reports Fourth Quarter and Full Fiscal Year 2020 Results PR Newswire NEWARK, N.J., Oct. 29, 2020 NEWARK, N.J. , Oct. 29, 2020 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $4.9 million and a loss per share of $0...

RFL - FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma

CRANBURY, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics announced today that the U.S. Food and Drug Administration (FDA) granted Orphan D...

RFL - Miragen Therapeutics, Titan Pharmaceuticals leads healthcare gainers; Neovasc, Akerna among major losers

Gainers: Miragen Therapeutics (MGEN) +86%, Titan Pharmaceuticals (TTNP) +62%, Community Health Systems (CYH) +35%, Scholar Rock Holding (SRRK) +7%, Rafael Holdings (RFL) +7%.Losers: Neovasc (NVCN) -44%, Akerna (KERN) -19%, Tiziana Li...
RFL - Rafael Pharmaceuticals Crosses Enrollment of 100th Patient in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

CRANBURY, N.J., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that it has crossed the enrollment of 100 patients in its Phase ...

RFL - Rafael Pharmaceuticals' lead compound CPI-613 on go with early-stage study for pancreatic cancer

Rafael Pharmaceuticals' ([[RFL]] +4.5%) partner Ono Pharmaceutical has commenced, a Phase 1 study of Rafael’s lead compound, CPI-613 in Japan for patients with pancreatic cancer.The study will evaluate the efficacy and safety of Rafael’s lead compound, C...

RFL - A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals' Lead Compound CPI-613®? (devimistat) for Patients With Pancreatic Cancer in Japan

CRANBURY, N.J., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics announced today its partner Ono Pharmaceutical Co., Ltd. (“Ono”...
Previous 10 Next 10